通过整合深度学习和分子建模来设计mIDH1抑制剂的De novo设计
Dingkang Sun1, Lulu Xu2, Mengfan Tong3
1College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China.
Frontiers in pharmacology
|November 8, 2024
概括
研究人员使用深度学习来设计异酸脱酶1 (IDH1) 基因的新抑制剂,该基因是急性髓性白血病和质瘤等癌症的关键驱动因素. 化合物M1显示出最好的结合特性,为癌症治疗开发提供了一个有希望的新途径.
科学领域:
- 药用化学 医学化学
- 计算机化药物设计技术
- 在瘤学瘤学.
背景情况:
- 异酸脱酶1 (IDH1) 基因的突变是急性髓性白血病,质瘤和其他固体瘤发展的关键驱动因素.
- 向突变IDH1 (mIDH1) 对这些癌症是一种有前途的治疗策略.
研究的目的:
- 使用先进的计算方法设计新的mIDH1抑制剂.
- 为了确定具有有利的药理动力学性质的强效和稳定的候选药物.
主要方法:
- 利用双向循环神经网络 (BRNN) 和脚手架跳跃技术来产生新型化学化合物.
- 采用主要成分分析,药物相似性的定量估计,合成可访问性和分子对接用于化合物评估.
- 进行了ADME预测,分子对接和分子动力学模拟,以评估与mIDH1.1的结合亲和力和稳定性.
主要成果:
- BRNN和脚手架跳跃分别产生了3890和3680个新化合物,BRNN生成的分子显示出优越的多样性,可药性和对接得分.
- 从BRNN产生的化合物中选择了具有高对接分数的十种结构多样化的候选药物.
- 分子动力学模拟证实了M1,M2,M3和M6化合物的稳定性,其中M1化合物表现出最好的结合特性和自由能量.
结论:
- 使用BRNN设计的M1,M2,M3和M6化合物对mIDH1.1具有最佳的结合特性.
- 这项研究代表了深度学习在设计mIDH1抑制剂方面的首次应用,为未来的药物发现工作提供了宝贵的理论指导.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
426
相关概念视频
02:00Molecular Models
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...